Rimonabant

Rimonabant (SR141716) is a highly potent, brain penetrated and selective central cannabinoid receptor (CB1) antagonist with a Ki of 1.8 nM. Rimonabant (SR141716) also inhibits Mycobacterial membrane protein Large 3 (MMPL3) .

Product Specifications

CAS Number

[168273-06-1]

Product Name Alternative

SR141716

UNSPSC

12352005

Hazard Statement

H301, H319

Target

Bacterial; Cannabinoid Receptor

Type

Reference compound

Related Pathways

Anti-infection; GPCR/G Protein; Neuronal Signaling

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Infection; Metabolic Disease; Cancer

Assay Protocol

https://www.medchemexpress.com/Rimonabant.html

Purity

99.52

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

ClC1=CC=C(C=C1)C2=C(C(C(NN3CCCCC3)=O)=NN2C4=CC=C(C=C4Cl)Cl)C

Molecular Formula

C22H21Cl3N4O

Molecular Weight

463.79

Precautions

H301, H319

References & Citations

[1]Seely KA, Brents LK, Franks LN, Rajasekaran M, Zimmerman SM, Fantegrossi WE, Prather PL. AM-251 and rimonabant act as direct antagonists at mu-opioid receptors: Implications for opioid/cannabinoid interaction studies. Neuropharmacology. 2012 Oct;63 (5) :905-15.|[2]Zhang B, et al. Crystal Structures of Membrane Transporter MmpL3, an Anti-TB Drug Target. Cell. 2019 Jan 24;176 (3) :636-648.e13.|[3]Erdozain, A. M. et al. The inverse agonist effect of rimonabant on G protein activation is not mediated by the cannabinoid CB1 receptor: Evidence from postmortem human brain Biochemical Pharmacology (2012), 83 (2), 260-268.|[4]Leite, C.E., et al. Rimonabant: An antagonist drug of the endocannabinoid system for the treatment of obesity. Pharmacol Rep 61 217-224 (2009) .

Shipping Conditions

Room Temperature

Storage Conditions

4°C (Powder, sealed storage, away from moisture)

Scientific Category

Reference compound1

Clinical Information

Launched

Isoform

CB1

Citation 01

Anal Chem. 2025 Jun 3;97 (21) :11099-11109.|Autophagy. 2021 Nov;17 (11) :3592-3606.|Cell. 2019 Jan 24;176 (3) :636-648.e13. |Int J Mol Sci. 2024 May 3;25 (9) :5012.|J Gerontol A Biol Sci Med Sci. 2025 Aug 28:glaf189.|J Psychopharmacol. 2025 Jul 31:2698811251355603.|Structure. 2022 Oct 6;30 (10) :1395-1402.e4.|Cancers (Basel) . 2021 Jan 18;13 (2) :330.|Int J Mol Sci. 2025 Jul 3;26 (13) :6409.|Molecules. 2025 Aug 28;30 (17) :3517.|Neuroscience. 2019 Apr 15:404:246-258.